Study Shows Cancer Vaccines Led to Long-Term Survival for Patients with Metastatic Melanoma and to Long Periods of Disease Control After Completion of Therapy
NEWPORT BEACH, Calif., July 28 /PRNewswire/ -- Hoag Memorial Hospital Presbyterian today announced promising data from a clinical study showing patient-specific cancer vaccines derived from patients' own cancer cells and immune cells were well tolerated and resulted in impressive lo...
Enrollment in Delcath's Pivotal Phase III Metastatic Melanoma Clinical Trial Achieves Seventy-Five Percent Accrual
NEW YORK, June 8 /PRNewswire-FirstCall/ -- Delcath Systems, Inc. (Nasdaq: DCTH ), a medical technology company testing its proprietary percutaneous hepatic perfusion (PHP(TM)) system for the treatment of cancers of the liver, announced today that it has achieved the seventy-five percent enroll...
Encouraging First Data on New Targeted Treatment for Patients With Melanoma - the Deadliest Form of Skin Cancer
PLX4032 (R7204) Phase I Results Offer Hope of First Highly Effective Drug in Melanoma
Along With Companion Diagnostic
BASEL, Switzerland, June 1 /PRNewswire/ -- Roche announced today results from a Phase I study with PLX4032 (R7204) a new, highly selective and promising treatment for patients...
AlphaVax Announces Promising Results in Melanoma Studies
RESEARCH TRIANGLE PARK, N.C., May 13 /PRNewswire/ -- AlphaVax announced today the presentation of promising results from a collaboration with researchers at the Memorial Sloan-Kettering Cancer Center (MSKCC). Francesca Avogadri, Ph.D., a Research Fellow in the Department of Medicine at MSKCC prese...
Phase 3 Trial of Nexavar in Chemotherapy-Naive Patients with Advanced Melanoma Does Not Meet Primary Endpoint
WAYNE, N.J. and EMERYVILLE, Calif., April 27 /PRNewswire-FirstCall/ -- Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) today announced that a Phase 3 trial evaluating Nexavar(R) (sorafenib) tablets in patients with unresectable stage III or stage IV melanoma
Multi-Pronged Therapeutic Cancer Vaccine Regimen to be Studied in Melanoma Patients
PARIS, and TORONTO, Sept. 17 /PRNewswire/ -- Sanofi pasteur, the
vaccines division of the sanofi-aventis Group, announced today that it is
sponsoring a Phase II clinical study exploring a multi-pronged treatment
approach to high risk and advanced-stage melanoma
-- an often fatal form of
U.S. NCI Starts Enrolment in Phase 2 Systemic Melanoma Clinical Trial with REOLYSIN(R)
CALGARY, Aug. 12 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.
("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that the U.S.
National Cancer Institute (NCI), part of the National Institutes of Health,
has started enrolment in a Phase 2 clinical trial for patients with
Eight-Year Melanoma Remission is Among Early Cancer Treatment Results
NASHVILLE, Tenn., July 14 /PRNewswire/ -- A newly available treatment
already has benefited several individuals with aggressive malignancies.
Offered through NeoPlas Innovation, this regimen has arrested or eradicated
tumors in more than 80% of initial patients. Director of Research Dr.
Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
EORTC 18991 Phase III Study Results Published in The Lancet
KENILWORTH, N.J., July 11 /PRNewswire-FirstCall/ -- Today,
Schering-Plough (NYSE: SGP ) and the EORTC announced that long-term
treatment with pegylated interferon alfa-2b in stage III melanoma
had a significant and sus...
Patient's Own Infection-Fighting T Cells Put Late-Stage Melanoma Into Long-Term Remission - Without Chemotherapy or Radiation
Case is first to show safety and effectiveness of using cloned cells alone to kill tumors
SEATTLE, June 18 /PRNewswire/ -- Researchers describe the first
successful use of a human patient's cloned infection-fighting T cells as
the sole therapy to put an advanced soli...
Study Supports Possible Use of Leukine(R) as a Potential Adjuvant Therapy for High-Risk Melanoma Patients
- Phase II Data Indicate Overall and Disease-Free Survival -
WAYNE, N.J., June 5 /PRNewswire/ -- Results from an adjuvant trial in
patients demonstrated that a majority of patients
treated with Leukine(R) (sargramostim) achieved disease-free and/or overall
Delcath Expands Phase III Trial for Metastatic Melanoma to Include St. Luke's Cancer Center
NEW YORK, June 3 /PRNewswire-FirstCall/ -- Delcath Systems, Inc.
(Nasdaq: DCTH ) announced today that the St. Luke's Cancer Center of
Bethlehem, PA, part of St. Luke's Hospital & Health Network (St. Luke's),
has joined Delcath's Phase III clinical trial for the treatment of
Anti-TGF-Beta Antisense AP 12009 Shows Very Good Safety and Tolerability in Systemic Treatment of Pancreatic Carcinoma, Malignant Melanoma and Colorectal Carcinoma
CHICAGO and REGENSBURG, Germany, June 2 /PRNewswire/ -- The TGF-beta 2
inhibitor AP 12009, developed by Antisense Pharma, reveals very good safety
and tolerability in the systemic treatment of pancreatic carcinoma,
and colorectal carcinoma. AP 12009, administered
BioVex Reports Positive Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting
CHICAGO, June 1 /PRNewswire/ -- BioVex Inc, a biotechnology company
developing clinical stage treatments for cancer and the prevention of
infectious disease, today announced positive results from its Phase II
clinical trial of OncoVEX GM-CSF, an oncolytic for the treatment of
BioVex to Report Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting
WOBURN, Mass., May 16 /PRNewswire/ -- BioVex Inc, a biotechnology
company developing clinical stage products in oncology and infectious
disease, announced today that the abstract describing the interim results
from its Phase II clinical trial of OncoVEX GM-CSF in advanced metastatic
Delcath Expands Phase III Trial for Metastatic Melanoma to Include University of Maryland Medical Center
NEW YORK, April 25 /PRNewswire-FirstCall/ -- Delcath Systems, Inc.
(Nasdaq: DCTH ) announced today that the Institutional Review Board (IRB) of
the University of Maryland Medical Center (UMMC) has approved UMMC's
participation in the Phase III study of the Company's Percutaneous Hepatic
Vical Promotes Melanoma Awareness Month With Allovectin-7(R) Video Report
SAN DIEGO, April 23 /PRNewswire-FirstCall/ -- Vical Incorporated
(Nasdaq: VICL ) today announced the release to television news stations
nationwide of an independently produced video report featuring metastatic
melanoma patients treated with the company's Allovectin-7(R)
BioVex Agrees SPA With the FDA for a Pivotal Study With OncoVEX(GM-CSF) in Metastatic Melanoma and Announces Presentation of Phase II Results at ASCO
FDA agrees to first SPA for an oncolytic product
WOBURN, Mass., April 22 /PRNewswire/ -- BioVex Inc, a biotechnology
company developing clinical stage treatments for cancer and the prevention
of infectious disease, announced today that the U.S. Food and Drug
Administration (FDA) ha...
New Study Shows Proprietary Canola Extract, Dermytol(TM), Produces Pronounced Decrease in Malignant Melanoma Tumor Volume
KGK Synergize Inc. Presents Findings Today
SAN DIEGO, April 7, 2008 /PRNewswire/ -- A new study presented at the
Experimental Biology Annual Meeting shows that a proprietary blend
extracted from canola, Dermytol(TM), produces a pronounced reduction of
IDM Pharma Announces Updated Phase 2 UVIDEM(R) Results Showing Durable Disease Control and Tolerability in Advanced Melanoma Patients
IRVINE, Calif., Nov. 2 /PRNewswire-FirstCall/ -- IDM Pharma, Inc.
(Nasdaq: IDMI ) today announced updated results from a Phase 2 UVIDEM(R)
vaccine clinical trial (DC-MEL-202). The updated results
showed that the investigational agent UVIDEM showed evidence of clinical
Genasense(R) Data in Patients with Advanced Melanoma to be Featured at 4th International Melanoma Congress
BERKELEY HEIGHTS, N.J., Oct. 24 /PRNewswire-FirstCall/ -- Genta
Incorporated (Nasdaq: GNTA ) announced that clinical data from the Company's
programs for Genasense(R) (oblimersen) in patients with advanced melanoma
will be featured at the 4th International Melanoma
Congress. The conference
Authorization for AGENDA Phase 3 Trial of Genasense(R) in Advanced Melanoma Granted by French Regulatory Agency
Decision Facilitates European Trial Opening in 13 New Sites
BERKELEY HEIGHTS, N.J., Oct. 17 /PRNewswire-FirstCall/ -- Genta
Incorporated (Nasdaq: GNTA ) announced that the French Health Products
Safety Agency ("AFSSAPS") has granted authorization to open the Company's
Phase 3 trial of G...
Recipient of Melanoma Drug in Development Celebrates Two Cancer-Free Years
KNOXVILLE, Tenn., Oct. 16 /PRNewswire/ -- When eighty-six-year-old
Keith Hora went to see Dr. Peter Hersey, a medical oncologist and professor
at the University of Newcastle in Australia, he was told he only had three
to six months to live. Hora had been diagnosed with stage III melanoma, one
Large Blinded Clinical Study Achieves High Accuracy for the Diagnosis of Melanoma Using In Vivo Confocal Microscopy
- Lesions non-invasively imaged in 5 to 10 minutes - - Landmark Study Reported in Journal of Investigative Dermatology -
ROCHESTER, N.Y., Sept. 18 /PRNewswire/ -- A landmark publication that
appeared in the Journal of Investigative Dermatology reports the results of
a large, two sit...
Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
Barcelona Hosts Key Investigator Meeting for European Participants in Phase 3 AGENDA Trial Targeting Biomarker-Defined Population
BERKELEY HEIGHTS, N.J., Sept. 5 /PRNewswire-FirstCall/ - Genta
Incorporated (Nasdaq: GNTA ) announced that data from the Company's Phase 3
trial of Genasense...
CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma
- Data presented at the 2008 iSBTc Annual Meeting -
- Conference call to be hosted today at 11:00 a.m. ET to discuss
BRANFORD, Conn., Nov. 3 /PRNewswire-FirstCall/ -- CuraGen Corporation
(Nasdaq: CRGN ) announced today preliminary data from an ongoing Phase II
trial of CR011-vcMM...
CuraGen Completes Enrollment in Phase II Trial of CR011-vcMMAE in Metastatic Melanoma
- Preliminary results to be presented on November 1, 2008 at 2008 iSBTc Annual Meeting -
BRANFORD, Conn., Sept. 11 /PRNewswire-FirstCall/ -- CuraGen Corporation
(Nasdaq: CRGN ), a clinical-stage biopharmaceutical company focused on
oncology, today announced that it ...
Journal of Clinical Oncology Publishes Leukine(R) Study Demonstrating Positive Survival Outcomes in Patients with High-Risk Melanoma
- Phase II Trial Shows Increase in Mature Dendritic Cells -
WAYNE, N.J., June 30 /PRNewswire-FirstCall/ -- Bayer HealthCare
Pharmaceuticals today confirmed that results of a Phase II trial were
published in the July 1 edition of the Journal of Clinical Oncology. The
study showed that Leu...
Genta Updates Progress of its Phase 3 Trial of Genasense(R) in Patients with Advanced Melanoma
Clinical Study on Track to Complete Accrual in Fourth Quarter 2008
BERKELEY HEIGHTS, N.J., June 24 /PRNewswire-FirstCall/ -- Genta
Incorporated (OTC Bulletin Board: GNTA) announced the presentation of a
progress update from an ongoing Phase 3 trial of Genasense(R) (oblimersen
CuraGen Announces Expansion of CR011-vcMMAE Phase II Trial in Melanoma
- RECIST-defined objective response supports expansion of Simon 2-Stage designed trial -
BRANFORD, Conn., June 11 /PRNewswire-FirstCall/ -- CuraGen Corporation
(Nasdaq: CRGN ), a clinical-stage biopharmaceutical company focused on
oncology, announced today that its ...
CuraGen Announces Data From Ongoing Phase I/II Trial Showing Clinical Activity of CR011-vcMMAE in Metastatic Melanoma
- Data presented at the 2008 ASCO Annual Meeting - - Conference call to be hosted Wednesday, June 4 at 9:00 a.m. EDT to discuss results -
BRANFORD, Conn., June 1 /PRNewswire-FirstCall/ -- CuraGen Corporation
(Nasdaq: CRGN ) today presented encouraging res...
Ipilimumab Plus Chemotherapy is Associated with Prolonged Survival and Increased Disease Control Rates in Patients with Advanced Melanoma
Updated Clinical Phase 2 data presented at American Society of Clinical Oncology Annual Meeting
PRINCETON, N.J., June 1 /PRNewswire-FirstCall/ -- Medarex, Inc.
(Nasdaq: MEDX ) today announced updated long-term follow-up and overall
survival (OS) results from a Phase 2 c...
New Data on MAGE-A3 Cancer Immunotherapy Support Potential Novel Options of Treating Non-Small Cell Lung Cancer and Melanoma
Gene Expression Profiling of Tumor is Correlated With Clinical Response
CHICAGO, May 30 /PRNewswire-FirstCall/ -- New data presented by
GlaxoSmithKline (GSK) today highlighted the potential of its
investigational MAGE-A3 Antigen-Specific Cancer Immunotherapeutic (ASCI)
through results of three...
Genasense(R) Chemotherapy Program Yields High Response Rate in Patients with Stage 4 Melanoma
Related Clinical Study Shows Potential Utility of Short-Course High-Dose Therapy
BERKELEY HEIGHTS, N.J., May 30 /PRNewswire-FirstCall/ -- Genta
Incorporated (OTC Bulletin Board: GNTA) announced preliminary results that
have shown a high objective response rate in...
Elesclomol Study Shows Significant Improvement in Progression-Free Survival for Chemotherapy-Naive Patients With Metastatic Melanoma
CHICAGO, May 20 /PRNewswire/ -- GlaxoSmithKline and Synta
Pharmaceuticals Corp. (Nasdaq: SNTA ) today announced positive Phase II
clinical data for elesclomol (formerly STA-4783), an investigational agent
currently in development for metastatic melanoma. A retrospective analysis
showed that s...
Micromet Presents Safety and Efficacy Data from Primate Studies With Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma
BETHESDA, Md., April 14 /PRNewswire-FirstCall/ -- Micromet, Inc.
(Nasdaq: MITI ), a biopharmaceutical company developing novel antibodies for
the treatment of cancer, inflammation and autoimmune diseases, today
presented at the Annual Meeting of the American Association for Cancer
DSMB Supports Continuation of Phase 3 AGENDA Trial of Genasense(R) in Advanced Melanoma
Completion of Target Enrollment Expected in Fourth Quarter
BERKELEY HEIGHTS, N.J., March 31 /PRNewswire-FirstCall/ -- Genta
Incorporated (Nasdaq: GNTA ) announced that the Data Safety Monitoring Board
(DSMB) for AGENDA, a Phase 3 trial of Genasense (oblimersen sodium)
Injection, which ...
AmpliMed Corporation Announces Promising 1-year Survival Data from Phase I/II Study of Amplimexon(R) in Metastatic Malignant Melanoma
TUCSON, Ariz., Jan. 3 /PRNewswire/ -- AmpliMed today reported one year
survival results from a Phase I/II trial of its lead drug candidate,
Amplimexon(R) (imexon for injection) in combination with dacarbazine in
patients with unresectable stage III or stage IV metastatic malignant
FDA to Extend Review of Data Quality Submission for Genasense(R) in Melanoma
BERKELEY HEIGHTS, N.J., Dec. 21 /PRNewswire-FirstCall/ -- Genta
Incorporated (Nasdaq: GNTA ) announced today that the Company has received
notice from the Food and Drug Administration (FDA) that FDA has extended
its review period of Genta's request for correction of certain information
CuraGen Announces Presentation of Phase I Dose-Escalation Results on CR011- vcMMAE for Metastatic Melanoma
- Initial clinical trial results suggesting safety and clinical activity of
CR011-vcMMAE reported at the AACR-NCI-EORTC International Conference -
BRANFORD, Conn., Oct. 24 /PRNewswire-FirstCall/ -- CuraGen Corporation
(Nasdaq: CRGN ), a clinical-stage biopharmaceutical company focused on